Laura Moore, MD
Family Medicine · Sugar Land, TXNPI 1043892987
Payments from drug & device makers
Across 27 payments — averaging $25.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$279
- Sumitomo Pharma America, Inc.$116
- Hologic Sales And Service, LLC$62
- Exact Sciences$54
- UCB, Inc.$47
- Lilly USA, LLC$32
- plus $107 from 5 others
What the payments were for
- Food & beverage$697100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 12 | $279 |
| Sumitomo Pharma America, Inc. | 3 | $116 |
| Hologic Sales And Service, LLC | 2 | $62 |
| Exact Sciences | 2 | $54 |
| UCB, Inc. | 1 | $47 |
| Lilly USA, LLC | 2 | $32 |
| Dynavax Technologies Corporation | 1 | $26 |
| Dexcom, Inc. | 1 | $24 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Merck | 1 | $20 |
| Inspire Medical Systems, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$100
How this compares
$697 in reported general payments places this provider in the 55th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 12 | $13,628 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 17 | $526 |
| Nifedipine ErNifedipine | 18 | $431 |
| Atorvastatin Calcium | 42 | $388 |
| Lisinopril | 21 | $276 |
| Losartan Potassium | 32 | $256 |
| Tamsulosin Hcl | 13 | $216 |
| Levothyroxine Sodium | 17 | $192 |
| Rosuvastatin Calcium | 17 | $176 |
| Famotidine | 16 | $155 |
| Gabapentin | 14 | $154 |
| Fluticasone Propionate | 13 | $145 |
| Amlodipine Besylate | 19 | $130 |
| Metformin Hcl | 24 | $95 |
| Escitalopram Oxalate | 11 | $92 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Sugar Land
- Wilner JeudySugar Land$6M
- Ronald PucilloSugar Land$5.1M
- Mehjabin ParkarSugar Land$3.9M
- John VanderzylSugar Land$3.8M
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.